On 26 February 2026, Celltrion reported that it plans to expand its biosimilar lineup to 18 products by 2030 with seven candidates that have either entered clinical development or for which investigational new drug applications are being prepared. Celltrion’s disclosed programmes include CT-P53 biosimilar to Ocrevus (ocrelizumab), CT-P55 biosimilar to Cosentyx (secukinumab) and CT-P52 biosimilar to Taltz (ixekizumab) in autoimmune diseases, as well as cancer therapies CT-P51 biosimilar to Keytruda (pembrolizumab) and CT-P44 biosimilar to Darzalex (daratumumab).
This announcement adds further detail to Celltrion’s commercialisation plans reported in January 2026.